Does Blocking VEGF from the Inside or the Outside of the Cell Make a Difference?
Volume 6, Issue 9 September 2007 Pages 1339 – 1340 DOI: 10.4161/cbt.6.9.5031 We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link: Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk. Angiogenesis inhibitors that block a tumor’s development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy. However, a new study by researchers at UCLA’s Jonsson Cancer Center showed that one method of blocking blood supply development could result in serious and potentially deadly side effects. Several newly developed angiogenesis inhibitors work by blocking vascular endothelial growth factor (VEGF), an important signaling protein that spurs growth of new blood vessels. Avastin, an approved angiogenesis inhibitor for colon and lung
